Price
No data yet.
Social Signal Score
Analyst Ratings
17 analystsRevenue
$22.84MAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Troy Wilson
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 260
- Beta
- 0.38
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -3.47
Financials
Revenue
$22.84M+837.6%Net Income
$-70.22MEBITDA
$-69.86MFree Cash Flow
$-54.89MEPS (diluted)
$-0.78Shares Outstanding (diluted)
89.82M+368.9%Operating Expenses
$97.13MCash & Debt
$492.10MRevenue by Segment (annual)
$67.48MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $67.48M | $-278.67M | $-3.18 |
| 2024 | $53.88M | $-173.98M | $-2.02 |
| 2023 | $0.00 | $-152.63M | $-2.08 |
| 2022 | $0.00 | $-135.84M | $-2.03 |
| 2021 | $0.00 | $-130.47M | $-1.97 |
| 2020 | $0.00 | $-89.63M | $-1.69 |
| 2019 | $0.00 | $-63.14M | $-1.51 |
| 2018 | $0.00 | $-60.45M | $-1.72 |
| 2017 | $0.00 | $-35.43M | $-1.52 |
| 2016 | $0.00 | $-27.56M | $-1.47 |
| 2015 | $0.00 | $-22.63M | $-2.28 |
| 2014 | $0.00 | $-11.01M | $-2.69 |
| 2013 | $0.00 | $-27.3K | $-0.01 |
| 2012 | $0.00 | $-27.0K | $-0.01 |
Valuation
KURAhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
113+61.90%Social Signal Score
Mentions (24)
- Newsseekingalpha.com·5d ago·Positive
Kura Oncology, Inc. (KURA) Presents at UBS Global Biopharma Conference 2026 Transcript Kura Oncology, Inc. ( KURA ) UBS Global Biopharma Conference 2026 November 17, 2026 8:20 AM EST Company Participants Jennifer Fulk - Chief Financial Officer Brian Powl - Chief Commercial Officer Mollie Leoni - Chief Medical Officer Conference Call Participants Xiaochuan Dai - UBS Investment Bank, Research Division Presentation Xiaochuan Dai UBS Investment Bank, Research Division All right. Great. Well, thank y…
View source ↗ - Newsseekingalpha.com·5d ago·Neutral
…ured event-driven position. KOMZIFTI prescriptions outpaced new starts, suggesting growing refills; patient-level persistence and treatment duration remain unproven. KURA's funding bridge beyond the first 2028 topline is plausible, not assured, and depends on milestones, eligible debt draws, product receipts, and spending discipline.
View source ↗ - Newsglobenewswire.com·9d ago·Neutral
Kura Oncology to Participate in Two Investor Conferences in November SAN DIEGO, Nov. 13, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences:
View source ↗ - Newszacks.com·12d ago·Neutral
Kura Oncology (KURA) Reports Q3 Loss, Beats Revenue Estimates Kura Oncology (KURA) came out with a quarterly loss of $0.78 per share versus the Zacks Consensus Estimate of a loss of $0.83. This compares to a loss of $0.85 per share a year ago.
View source ↗ - Newszacks.com·16d ago·Neutral
Kura Oncology (KURA) Loses 35.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner Kura Oncology (KURA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
View source ↗ - Newszacks.com·26d ago·Neutral
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
View source ↗ - Newsmarketbeat.com·40d ago·Neutral
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor Kura Oncology NASDAQ: KURA and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell expansion, improved glucose control and sustained effects after treatment ended.
View source ↗ - Newsseekingalpha.com·40d ago·Positive
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
View source ↗ - Newsglobenewswire.com·40d ago·Neutral
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes – EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept study to assess safety and endogenous insulin production – – Investor webcast today, October 13, 2026, at 4:30 p.m. ET / 1:30 p.m.
View source ↗ - Newsglobenewswire.com·46d ago·Neutral
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –
View source ↗ - Newsglobenewswire.com·54d ago·Positive
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for Diabetes – KO-7246 regenerated functional β - cell mass and produced durable glycemic control in Type 1 and Type 2 diabetes models –
View source ↗ - Newsseekingalpha.com·67d ago·Positive
Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Kura Oncology, Inc. (KURA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsglobenewswire.com·75d ago·Neutral
…ercial operations, R&D portfolio management, investor relations, and capital allocation – SAN DIEGO, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced the appointment of Jennifer Fulk as Chief Financial Officer, effective September 8, 2026.
View source ↗ - Newszacks.com·82d ago·Positive
KURA Stock Gains 37.6% in a Month: Here's What You Need to Know Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.
View source ↗ - Newsglobenewswire.com·82d ago·Neutral
Kura Oncology to Participate in Three Investor Conferences in September SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that management will present at the following investor conferences: Wells Fargo Healthcare ConferenceSeptember 8, 20263:45 p.m.
View source ↗ - Newszacks.com·83d ago·Positive
Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock? Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
View source ↗ - Newsseekingalpha.com·88d ago·Positive
Kura Oncology: 'Strong Buy': Ziftomenib AML Expansions With Different Regimens Could Boost KOMZIFTI's Prospects Kura Oncology maintains a “Strong Buy” rating, driven by KOMZIFTI's FDA approval and robust early commercial performance in relapsed/refractory NPM1-mutated AML. The company achieved $9.1M net product revenue in two quarters, marking a 57% sequential increase, and targets significant market expansion via first-line AML indications. Phase 3 KOMET-017 trial topline data in 2028 and two p
View source ↗ - Newszacks.com·95d ago·Positive
Kura Oncology (KURA) is a Great Momentum Stock: Should You Buy? Does Kura Oncology (KURA) have what it takes to be a top stock pick for momentum investors? Let's find out.
View source ↗ - Newszacks.com·96d ago·Positive
Does Kura Oncology (KURA) Have the Potential to Rally 178.55% as Wall Street Analysts Expect? The mean of analysts' price targets for Kura Oncology (KURA) points to a 178.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
View source ↗ - Newsseekingalpha.com·102d ago·Positive
Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript Kura Oncology, Inc. (KURA) Q2 2026 Earnings Call Transcript
View source ↗ - Newsmarketbeat.com·102d ago·Negative
Kura Oncology Q2 Earnings Call Highlights Kura Oncology NASDAQ: KURA reported second-quarter net product revenue of $9.1 million from KOMZIFTI, its treatment for relapsed or refractory NPM1-mutated acute myeloid leukemia, as the company said the drug captured a majority share of new patient starts in the menin inhibitor market for that indication.
View source ↗ - Newszacks.com·102d ago·Neutral
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates Kura Oncology (KURA) came out with a quarterly loss of $0.77 per share versus the Zacks Consensus Estimate of a loss of $0.89. This compares to a loss of $0.75 per share a year ago.
View source ↗ - Newsglobenewswire.com·102d ago·Neutral
Kura Oncology Reports Second Quarter 2026 Financial Results – KOMZIFTI ® (ziftomenib) generated $9.1 million in net product revenue, up 57% over 1Q, and approximately 115 new patient starts, up 35% over 1Q –
View source ↗ - Newsglobenewswire.com·104d ago·Neutral
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib's Differentiated Binding Profile and Preclinical Activity – Publication details the discovery and preclinical characterization of ziftomenib, including its potency, selectivity, and mechanism of action –
View source ↗
Earnings
Thu, Mar 4(in 3 months)
Consensus estimate $-0.81 per share
Typical surprise -27.8% (median, so one quarter with a near-zero estimate can't distort it)
- Tue, Nov 10$-0.78 vs $-0.82beat
- Wed, Aug 12$-0.77 vs $-0.88beat
- Tue, May 12$-0.83 vs $-0.88beat
- Thu, Mar 5$-0.92 vs $-0.72miss
- Tue, Nov 4$-0.85 vs $-0.57miss
- Thu, Aug 7$-0.75 vs $0.15miss
Estimates and results for KURA via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by KURA officers and directors.
- Bought
- $5.4m
- Sold
- $4.8m
6 trades
53 trades
- Powl Brian T.sold
- Leoni Molliesold
- Powl Brian T.sold
- Ford Kathleensold
- Doyle Thomas Jamessold
- Leoni Molliesold
- Powl Brian T.sold
- Bair Teresa Brophysold
41 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Chris Jacobshouse · NY27 · disclosed Jan 20, 2023 (39d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
